Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Post tuberculosis treatment infectious complications.

Hsu D, Irfan M, Jabeen K, Iqbal N, Hasan R, Migliori GB, Zumla A, Visca D, Centis R, Tiberi S.

Int J Infect Dis. 2020 Mar;92S:S41-S45. doi: 10.1016/j.ijid.2020.02.032. Epub 2020 Feb 27.

2.

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

Sorino C, Negri S, Spanevello A, Visca D, Scichilone N.

Eur J Intern Med. 2020 Feb 26. pii: S0953-6205(20)30068-6. doi: 10.1016/j.ejim.2020.02.023. [Epub ahead of print] Review.

PMID:
32113944
3.

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network.

Int J Infect Dis. 2020 Mar;92S:S15-S25. doi: 10.1016/j.ijid.2020.01.042. Epub 2020 Feb 4.

4.

Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients.

Akkerman OW, Ter Beek L, Centis R, Maeurer M, Visca D, Muñoz-Torrico M, Tiberi S, Migliori GB.

Int J Infect Dis. 2020 Mar;92S:S10-S14. doi: 10.1016/j.ijid.2020.01.029. Epub 2020 Jan 23.

5.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
6.

Something is changing in adherence to CPAP therapy: real world data after 1 year of treatment in patients with obstructive sleep apnoea.

Morrone E, Giordano A, Carli S, Visca D, Rossato F, Godio M, Paracchini E, Rossi S, Balbi B, Sacco C, Braghiroli A.

Eur Respir J. 2020 Mar 5;55(3). pii: 1901419. doi: 10.1183/13993003.01419-2019. Print 2020 Mar. No abstract available.

PMID:
31806711
7.

Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2020 Feb 6;55(2). pii: 1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb. No abstract available.

PMID:
31699838
8.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2020 Feb 20;55(2). pii: 1901681. doi: 10.1183/13993003.01681-2019. Print 2020 Feb. No abstract available.

PMID:
31699833
9.

Pulmonary rehabilitation: promising nonpharmacological approach for treating asthma?

Zampogna E, Spanevello A, Visca D.

Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):80-84. doi: 10.1097/ACI.0000000000000597.

PMID:
31633568
10.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Dec 19;54(6). pii: 1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.

PMID:
31601711
11.

Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL.

ERJ Open Res. 2019 Sep 16;5(3). pii: 00118-2019. doi: 10.1183/23120541.00118-2019. eCollection 2019 Jul. Review.

12.

Correction to: When kidneys and lungs suffer together.

Sorino C, Scichilone N, Pedone C, Negri S, Visca D, Spanevello A.

J Nephrol. 2020 Feb;33(1):187. doi: 10.1007/s40620-019-00643-w.

PMID:
31529293
13.

Is Two Better Than One? The Impact of Doubling Training Volume in Severe COPD: A Randomized Controlled Study.

Paneroni M, Vogiatzis I, Belli S, Savio G, Visca D, Zampogna E, Aliani M, Carolis V, Maniscalco M, Simonelli C, Vitacca M.

J Clin Med. 2019 Jul 18;8(7). pii: E1052. doi: 10.3390/jcm8071052.

14.

Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis.

Zampogna E, Centis R, Negri S, Fiore E, Cherubino F, Pignatti P, Heffler E, Canonica GW, Sotgiu G, Saderi L, Migliori GB, Spanevello A, Visca D.

J Asthma. 2019 Aug 13:1-7. doi: 10.1080/02770903.2019.1646271. [Epub ahead of print]

PMID:
31317799
15.

Effectiveness of a Pulmonary Rehabilitation Program on Persistent Asthma Stratified for Severity.

Zampogna E, Paneroni M, Cherubino F, Pignatti P, Rudi M, Casu G, Vitacca M, Spanevello A, Visca D.

Respir Care. 2019 Dec;64(12):1523-1530. doi: 10.4187/respcare.06761. Epub 2019 Jul 16.

PMID:
31311850
16.

Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients.

Pignatti P, Visca D, Cherubino F, Zampogna E, Lucini E, Saderi L, Sotgiu G, Spanevello A.

Respir Res. 2019 Jul 10;20(1):145. doi: 10.1186/s12931-019-1111-1.

17.

Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Tiberi S, Torrico MM, Rahman A, Krutikov M, Visca D, Silva DR, Kunst H, Migliori GB.

J Bras Pneumol. 2019 Apr 25;45(2):e20180324. doi: 10.1590/1806-3713/e20180324. Review. English, Portuguese.

18.

Adherence to Continuous Positive Airway Pressure in patients with Obstructive Sleep Apnoea. A ten year real life study.

Zampogna E, Spanevello A, Lucioni AM, Facchetti C, Sotgiu G, Saderi L, Ambrosino N, Visca D.

Respir Med. 2019 Apr;150:95-100. doi: 10.1016/j.rmed.2019.02.017. Epub 2019 Mar 1.

PMID:
30961958
19.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

20.

Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.

Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D'Ambrosio L, Pegoraro V, Pignatti P, Muňoz-Torrico M, Migliori GB, Spanevello A.

Eur Respir J. 2019 Mar 14;53(3). pii: 1802184. doi: 10.1183/13993003.02184-2018. Print 2019 Mar. No abstract available.

PMID:
30872556
21.

When kidneys and lungs suffer together.

Sorino C, Scichilone N, Pedone C, Negri S, Visca D, Spanevello A.

J Nephrol. 2019 Oct;32(5):699-707. doi: 10.1007/s40620-018-00563-1. Epub 2018 Dec 6. Review. Erratum in: J Nephrol. 2019 Sep 16;:.

PMID:
30523563
22.

Relationship between diabetes and respiratory diseases-Clinical and therapeutic aspects.

Visca D, Pignatti P, Spanevello A, Lucini E, La Rocca E.

Pharmacol Res. 2018 Nov;137:230-235. doi: 10.1016/j.phrs.2018.10.008. Epub 2018 Oct 9. Review.

PMID:
30312663
23.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

24.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
26.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

27.

Tuberculosis elimination: where are we now?

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho ACC, Centis R, D'Ambrosio L, Visca D, Spanevello A, Battista Migliori G.

Eur Respir Rev. 2018 Jun 13;27(148). pii: 180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30. Review.

28.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Review. Portuguese, English.

29.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

30.

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD.

Donner CF, Amaducci S, Bacci E, Baldacci S, Bartoli ML, Beghi GM, Benfante A, Brighindi S, Casali L, Castiglia D, Cazzola M, Celi A, Cianchetti S, Colombo G, Crimi C, Dente FL, Di Maria G, Di Maria A, Latorre M, Lavorini F, Maio S, Mannini C, Messina R, Paggiaro PL, Pignatti P, Price D, Scichilone N, Simoni M, Spanevello A, Stagno d'Alcontres M, Tan S, Torchio R, Viegi G, Visca D, Wouters EFM, Yu Hui Xin S.

Monaldi Arch Chest Dis. 2018 Feb 2;88(1):886. doi: 10.4081/monaldi.2018.886.

31.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477. Review.

PMID:
29470252
32.

DEVELOPING RADIATION RESISTANT THERMAL NEUTRON DETECTORS FOR THE E_LIBANS PROJECT: PRELIMINARY RESULTS.

Treccani M, Bedogni R, Pola A, Costa M, Monti V, Sans Planell O, Romano M, Durisi E, Visca DL, Bortot D, Gomez-Ros JM, Ferrero M, Anglesio S, Giannini G, Alikaniotis K.

Radiat Prot Dosimetry. 2018 Aug 1;180(1-4):304-308. doi: 10.1093/rpd/ncx298.

PMID:
29361156
33.

Airway inflammatory phenotypes: Making sputum cell evaluation more accessible for clinical use.

Pignatti P, Visca D, Leoni V, Zampogna E, Cherubino F, Sotgiu G, Lucini E, Spanevello A.

Clin Respir J. 2018 May;12(5):1989-1990. doi: 10.1111/crj.12747. Epub 2017 Dec 21. No abstract available.

PMID:
29193790
34.

Is bronchodilator the correct treatment for COPD subjects before EBUS?

Leoni V, Pignatti P, Visca D, Spanevello A.

J Thorac Dis. 2017 May;9(Suppl 5):S410-S413. doi: 10.21037/jtd.2017.03.142. Review.

35.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

36.

World TB Day 2017: Strengthening the fight against TB.

Solovic I, Centis R, D'Ambrosio L, Visca D, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e1-e4. doi: 10.1016/j.lpm.2017.02.002. No abstract available.

PMID:
28336002
37.

Classifying new anti-tuberculosis drugs: rationale and future perspectives.

Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Caminero Luna JA.

Int J Infect Dis. 2017 Mar;56:181-184. doi: 10.1016/j.ijid.2016.10.026. Epub 2016 Nov 3.

38.

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.

Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, Antoniou KM.

Eur Respir Rev. 2015 Jun;24(136):327-39. doi: 10.1183/16000617.00009114. Review.

39.

Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases.

Aliberti S, Messinesi G, Gamberini S, Maggiolini S, Visca D, Galavotti V, Giuliani F, Cosentini R, Brambilla AM, Blasi F, Scala R, Carone M, Luisi F, Harari S, Voza A, Esquinas A, Pesci A.

BMC Pulm Med. 2014 Dec 5;14:194. doi: 10.1186/1471-2466-14-194.

40.

Cardiovascular function in pulmonary emphysema.

Visca D, Aiello M, Chetta A.

Biomed Res Int. 2013;2013:184678. doi: 10.1155/2013/184678. Epub 2013 Dec 3. Review.

41.

Ventilatory response to carbon dioxide output in subjects with congestive heart failure and in patients with COPD with comparable exercise capacity.

Teopompi E, Tzani P, Aiello M, Ramponi S, Visca D, Gioia MR, Marangio E, Serra W, Chetta A.

Respir Care. 2014 Jul;59(7):1034-41. doi: 10.4187/respcare.02629. Epub 2013 Sep 17.

42.

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA.

J Rheumatol. 2013 Apr;40(4):435-46. doi: 10.3899/jrheum.120725. Epub 2013 Feb 1.

PMID:
23378460
43.

Ambulatory oxygen in interstitial lung disease.

Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, Wells AU, Renzoni EA.

Eur Respir J. 2011 Oct;38(4):987-90. doi: 10.1183/09031936.00190710. No abstract available.

44.

Fecal calprotectin concentrations in alcoholic patients: a longitudinal study.

Montalto M, Gallo A, Ferrulli A, Visca D, Campobasso E, Cardone S, D'Onofrio F, Santoro L, Covino M, Mirijello A, Leggio L, Gasbarrini G, Addolorato G.

Eur J Gastroenterol Hepatol. 2011 Jan;23(1):76-80. doi: 10.1097/MEG.0b013e32834101f9.

PMID:
21030869
45.

Classification of malabsorption syndromes.

Montalto M, Santoro L, D'Onofrio F, Curigliano V, Visca D, Gallo A, Cammarota G, Gasbarrini A, Gasbarrini G.

Dig Dis. 2008;26(2):104-11. doi: 10.1159/000116767. Epub 2008 Apr 21. Review.

PMID:
18431059
46.

Adverse reactions to food: allergies and intolerances.

Montalto M, Santoro L, D'Onofrio F, Curigliano V, Gallo A, Visca D, Cammarota G, Gasbarrini A, Gasbarrini G.

Dig Dis. 2008;26(2):96-103. doi: 10.1159/000116766. Epub 2008 Apr 21. Review.

PMID:
18431058
47.

Intestine: organ or apparatus?

Gasbarrini G, Montalto M, Santoro L, Curigliano V, D'Onofrio F, Gallo A, Visca D, Gasbarrini A.

Dig Dis. 2008;26(2):92-5. doi: 10.1159/000116765. Epub 2008 Apr 21.

PMID:
18431057

Supplemental Content

Support Center